Try our beta test site
607 studies found for:    "Keratoconjunctivitis sicca"
Show Display Options
Rank Status Study
1 Completed Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: Lotemax Gel + Restasis;   Drug: Lotemax Gel;   Drug: Restasis
2 Completed
Has Results
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: CF101;   Drug: Placebo
3 Completed Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: cyclosporine;   Drug: vehicle of OTX-101
4 Completed Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: Pimecrolimus
5 Completed Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
Condition: Keratoconjunctivitis Sicca
Interventions: Dietary Supplement: Hydroeye;   Other: Inactive Capsule
6 Completed Study of Rebamipide Eye Drops to Treat Dry Eye
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: Rebamipide
7 Completed Study of Rebamipide Eye Drops to Treat Dry Eye
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: Rebamipide
8 Enrolling by invitation An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: OTX-101 0.09%
9 Completed
Has Results
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: R348 Ophthalmic Solution, 0.2%;   Drug: R348 Ophthalmic Solution, 0.5%;   Drug: Placebo
10 Terminated Omega-3 Fatty Acid Supplements and Dry Eye
Condition: Keratoconjunctivitis Sicca
Interventions: Dietary Supplement: Omega-3 Fatty Acid;   Dietary Supplement: Soybean Soft Gels
11 Completed A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: voclosporin ophthalmic solution
12 Completed A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: Retaine™
13 Active, not recruiting A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: 1% Tavilermide Ophthalmic Solution;   Drug: Placebo Ophthalmic Solution
14 Completed Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: INS365 Ophthalmic Solution
15 Completed Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca
Conditions: Keratoconjunctivitis Sicca;   Dry Eye Syndrome
Intervention: Drug: dexamethasone, artificial tears
16 Active, not recruiting A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: 1% Tavilermide Ophthalmic Solution;   Drug: Placebo Ophthalmic Solution
17 Completed A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: R348 Ophthalmic Solution, 0.2%;   Drug: R348 Ophthalmic Solution, 0.5%;   Drug: R348 Ophthalmic Solution, 1.0%;   Drug: Placebo
18 Completed
Has Results
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
Condition: Keratoconjunctivitis Sicca
Intervention:
19 Withdrawn A Study Of Tasocitinib In Dry Eye Subjects
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: Tasocitinib;   Drug: vehicle for Tasocitinib
20 Completed A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: SkQ1;   Drug: Placebo SkQ1 (Vehicle)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.